CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Inclusion Criteria: * Histologically and cytologically confirmed B-cell NHL that has relapsed from, or is refractory to, all standard therapies (including autologous transplantation) known to provide clinical benefit, but have not been treated with bendamustine for their lymphoma * Must have measurable disease (e.g., a tumor mass \> 1 cm) * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Expected survival \> 3 months * Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device \[IUD\], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation * Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists * At least 2 weeks must have elapsed from any prior surgery * Aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT/serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x upper normal limit (UNL) (=\< 5 x UNL if liver metastases present) * Bilirubin =\< 1.5 x UNL * Serum creatinine =\< 1.5 mg/dL or 133 umol/L * "International normalized ratio" or INR must be =\< 1.5 * No evidence of active infection and no serious infection within the past month * Mentally competent, ability to understand and willingness to sign the informed co…